Caroline Campbell
General Practice · New York, NYNPI 1538651385
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,414, more than ten times the $231 reported in 2021. Among general practice clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $62.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$986
- Incyte Corporation$841
- Galderma Laboratories, L.p.$636
- AbbVie$570
- Organon$485
- UCB, Inc.$371
- plus $3K from 20 others
Across 10 payments — averaging $4516.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$27K
- Novartis$16K
- Eli Lilly$1K
What the payments were for
- Food & beverage$6,23395%
- Education$3425%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 10 | $986 |
| Incyte Corporation | 17 | $841 |
| Galderma Laboratories, L.p. | 6 | $636 |
| AbbVie | 7 | $570 |
| Organon | 6 | $485 |
| UCB, Inc. | 6 | $371 |
| Regeneron Healthcare Solutions, Inc. | 7 | $338 |
| Johnson & Johnson | 7 | $326 |
| Boehringer Ingelheim | 3 | $262 |
| Janssen Scientific Affairs, LLC | 4 | $230 |
| Pfizer | 4 | $195 |
| Arcutis Biotherapeutics, Inc. | 3 | $194 |
| Novartis | 2 | $186 |
| E.r. Squibb & Sons, L.L.C. | 4 | $174 |
| Almirall LLC | 1 | $134 |
| Dermavant Sciences, Inc. | 1 | $125 |
| Medtronic | 1 | $104 |
| LEO Pharma Inc. | 4 | $95 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $92 |
| Sun Pharmaceutical Industries Inc. | 3 | $71 |
| LEO Pharma AS | 1 | $38 |
| Merz North America, Inc. | 2 | $30 |
| Sanofi | 1 | $28 |
| Amgen | 1 | $23 |
| Blueprint Medicines Corporation | 1 | $23 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,575 in reported general payments places this provider in the 95th percentile of 5,764 general practice providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 13 | $48,649 |
| OpzeluraRuxolitinib Phosphate | 17 | $31,746 |
| Tacrolimus | 43 | $9,081 |
| Clobetasol Propionate | 72 | $5,935 |
| Ketoconazole | 72 | $1,814 |
| Metronidazole | 13 | $946 |
| Triamcinolone Acetonide | 40 | $566 |
| Clindamycin Phosphate | 11 | $278 |
| Spironolactone | 11 | $254 |
| Mupirocin | 14 | $108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $841 | $31,74617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,764 general practice providers in New York.
Other general practice in New York
- Ronnie MyersNew York$464K
- Alejandra Gonzalez-DuarteNew York$183K
- Laila AkhlaghiNew York$52K
- Vezire SarakNew York$39K
- Yohan KimNew York$38K
- Christine SkordelesNew York$32K
- Jose GorisNew York$23K
- Bruce YaffeNew York$22K
- Joseph PantaleoNew York$14K
- Jeffrey ShapiroNew York$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.